Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117547 | 1.00 | MMP1 (0.36) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL14375602 | 1.00 | MMP1 (0.36) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL14117600 | 0.85 | PDF (0.33) | — | |
| SCHEMBL8242004 | 0.85 | PDF (0.33) | — | |
| SCHEMBL8427639 | 0.83 | MMP1 (0.35) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL14117559 | 0.83 | MMP1 (0.38) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL14117568 | 0.83 | CTSK (0.33) | GRIK1GRIK2 | |
| SCHEMBL8244384 | 0.83 | CTSK (0.33) | GRIK1GRIK2 | |
| SCHEMBL14375684 | 0.83 | MMP1 (0.38) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL8241861 | 0.83 | MMP1 (0.38) | MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304056-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | MMP1 4532/4885MMP2 4030/4885MMP3 4395/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | MMP1 3143/4885MMP2 2099/4885MMP3 3633/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | MMP1 4204/4885MMP2 3672/4885MMP3 4243/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | MMP1 4204/4885MMP2 3672/4885MMP3 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.